BNC Wealth Management LLC Sells 149 Shares of Novo Nordisk A/S (NYSE:NVO)

BNC Wealth Management LLC lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 6,806 shares of the company’s stock after selling 149 shares during the period. BNC Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $585,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Strategic Investment Solutions Inc. IL bought a new position in Novo Nordisk A/S during the second quarter worth $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S during the third quarter worth $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S during the third quarter worth $42,000. Carolina Wealth Advisors LLC bought a new position in Novo Nordisk A/S during the third quarter worth $48,000. Finally, M&R Capital Management Inc. raised its stake in Novo Nordisk A/S by 260.5% during the third quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after buying an additional 297 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NVO. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Down 5.2 %

Shares of NYSE NVO opened at $78.74 on Friday. The stock has a market capitalization of $353.33 billion, a P/E ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45. The company has a 50-day moving average price of $97.76 and a 200-day moving average price of $117.23. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.